Boris Quednow
Professor of Psychiatry and Psychopharmacology
Data updated
Research Footprint
Boris Quednow appears in 11 tracked papers (2007–2026), most studied alongside MDMA, DMT and Ayahuasca, across Healthy Volunteers, Interpersonal Functioning & Social Connectedness and Medicinal Chemistry & Drug Development.
Most-cited paper: MDMA enhances emotional empathy and prosocial behavior (355 citations).
Frequent co-authors: Milan Scheidegger, Helena Aicher and Dominik Dornbierer.
Publication Landscape
How the 11 papers Blossom tracks for Boris Quednow line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Boris Quednow's publishing grown?
SourcedTracked papers by publication year; 2 earlier papers published before 2012. Click a year for the running total.
Don't read as total output: only the 11 of 11 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Boris Quednow publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Boris Quednow publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Boris B. Quednow is a clinician‑scientist whose work sits at the intersection of psychopharmacology, neuropsychiatry and experimental medicine. He has led and contributed to controlled human studies examining the behavioural and neurochemical effects of recreational and therapeutic psychoactive compounds, including comparative investigations of MDMA and methamphetamine, magnetic resonance spectroscopy studies of glutamate and GABA in relation to chronic MDMA use, neurophysiological assessments of conflict monitoring and emotional processing, and factorial dose‑escalation work probing the pharmacokinetic and pharmacodynamic interaction between N,N‑dimethyltryptamine (DMT) and the monoamine oxidase inhibitor harmine in healthy volunteers.
Key Impact
A leading translational researcher known for experimental studies on MDMA, methamphetamine and serotonergic compounds that link neurochemical and neurophysiological measures to social‑cognitive and behavioural outcomes.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Boris Quednow's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Boris Quednow is associated with.
Psychiatric University Hospital, Zurich
The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →